Glycoprotein IIb/IIIa antagonists - From bench to practice

Cellular and Molecular Life Sciences

Volumn 59, Issue 3, 2002, Pages 478-500

  Casserly, I P ^a,b   Topol, E J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

IIb 3 receptor; Acute coronary syndrome; Glycoprotein IIb IIIa inhibitor; Myocardial infarction; Percutaneous intervention; Platelet; Thrombosis

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; LAMIFIBAN; LEDRAFIBAN; LOTRAFIBAN; OROFIBAN; ROXIFIBAN; SIBRAFIBAN; TIROFIBAN; TM 337; UNCLASSIFIED DRUG; XEMILOFIBAN; XUBRIX;

CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

ANGINA, UNSTABLE; APOPTOSIS; BLOOD PLATELETS; CLINICAL TRIALS; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN CONFORMATION; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 0036207521     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-002-8440-8     Document Type: Review

References (173)

1. Coronary arteriographic findings in acute transmural myocardial infarction
2. Thrombosis in acute coronary syndromes and coronary interventions
3. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis
4. Porcine model of stent thrombosis: Platelets are the primary component of acute stent closure
5. Congenital bleeding disorders with long bleeding time and normal platelet count
6. Platelet membrane defects in Glanzmann's thrombasthenia: Evidence for decreased amounts of two major glycoproteins
7. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia
8. The formation of Ca++-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis
9. Structure and function of cell adhesion molecules
10. Adhesion molecules-part 1
11. The human platelet alphaIIb gene is not closely linked to its integrin partner beta3
12. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain
13. Ligand binding to integrin alphaIIbbeta3 is dependent on a MIDAS-like domain in the beta3 subunit
14. Assignment of disulphide bonds in human platelet GPIIIa: A disulphide pattern for the beta-subunits of the integrin family
15. Divalent cations differentially regulate integrin alphaIIb cytoplasmic tail binding to beta3 and to calcium- and integrin-binding protein
16. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy
17. A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3
18. Identification of a region in the integrin beta3 subunit that confers ligand binding specificity
19. Tyrosine phosphorylation of the beta3 cytoplasmic domain mediates integrin-cytoskeletal interactions
20. Integrins and actin filaments: Reciprocal regulation of cell adhesion and signaling
21. Identification of a talin-binding site in the integrin beta(3) subunit distinct from the NPLY regulatory motif of post-ligand binding functions: The talin N-terminal head domain interacts with the membrane-proximal region of the beta(3) cytoplasmic tail
22. Identification of an interaction between the mband protein skelemin and beta-integrin subunits: Colocalization of a skelemin-like protein with beta1- and beta3-integrins in non-muscle cells
23. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
24. The machinery of cell crawling
25. The elegant platelet: Signals controlling actin assembly
26. Molecular mechanisms of platelet exocytosis: Requirements for alpha-granule release
27. Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells
28. Nitric oxide and platelet aggregation
29. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets
30. Cyclic AMP-dependent phosphorylation of thromboxane A(2) receptor-associated Galpha(13)
31. Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase
32. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39
33. Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor alpha-receptor
34. Thromboxane A(2) receptors: Where have you gone?
35. Thrombin signalling and protease-activated receptors
36. Signaling through platelet integrin alpha IIb beta 3: Inside-out, outside-in, and sideways
37. Integrin signaling: The platelet paradigm
38. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex
39. Regulation of integrin affinity states through an NPXY motif in the beta subunit cytoplasmic domain
40. On the role of calpain and Rho proteins in regulating integrin-induced signaling
41. The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for fibrinogen
42. The regulation of growth and intracellular signaling by integrins
43. Glycoprotein IIb/IIIa in platelet aggregation and acute arterial thrombosis
44. The molecular adapter SLP-76 relays signals from platelet integrin alphaIIbbeta3 to the actin cytoskeleton
45. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function
46. Identification of shc as the primary protein binding to the tyrosine-phosphorylated beta 3 subunit of alphaIIbbeta3 during outside-in integrin platelet signaling
47. Fibrin clot retraction by human platelets correlates with alpha(IIb)beta(3) integrin-dependent protein tyrosine dephosphorylation
48. Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase
49. Lipid signalling
50. D3 phosphoinositides and outside-in integrin signaling by glycoprotein IIb-IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12-myristate 13-acetate
51. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation
52. Thrombin-stimulated human platelets express molecular forms of alpha-granule factor V (FV), which differ from FVa
53. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups
54. Intact platelet membranes, not platelet-released microvesicles, support the procoagulant activity of adherent platelets
55. Networking in the hemostatic system: Integrin alphaIIbbeta3 binds prothrombin and influences its activation
56. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
57. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40
58. Adhesion of activated platelets to endothelial cells: Evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM- 1), alphavbeta3 integrin, and GPIbalpha
59. Selectin-mediated rolling of neutrophils on immobilized platelets
60. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor
61. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factor AB
62. Interactions ofneutrophils and coagulation proteins
63. Localization of PDGF-B protein in macrophages in all phases of atherogenesis
64. Endothelial cells inhibit flow-induced smooth muscle cell migration: Role of plasminogen activator inhibitor- 1
65. PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon
66. Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine
67. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)
68. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors
69. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
70. Rapid platelet-function assay: An automated and quantitative cartridge-based method
71. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty
72. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition
73. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention
74. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
75. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors
76. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: With a review of platelet-leukocyte interactions
77. Potential non-glycoprotein IIb/IIIa effects of abciximab
78. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
79. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina
80. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
81. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
82. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-assessing ultegra) multicenter study
83. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
84. Variable interindividual responses to antiplatelet therapies - Do they exist, can we measure them, and are they clinically relevant?
85. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
86. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
87. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
88. Clinical pharmacology of eptifibatide
89. RGD-containing peptides inhibit fibrinogen binding to platelet alpha(IIb)beta3 by inducing an allosteric change in the amino-terminal portion of alpha(IIb)
90. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
91. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
92. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
93. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: Prospective analysis from pursuit
94. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention
95. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp
96. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors
97. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
98. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
99. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
100. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
101. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
102. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE trial investigators. Evaluation of oral xemilofiban in controlling thrombotic events
103. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial
104. Oral platelet glycoprotein IIb/IIIa blockade
105. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Thrombolysis in myocardial infarction
106. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial
107. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist
108. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation
109. Antithrombotic effects of abciximab
110. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A timi 14 substudy
111. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: Angiographic results from the PRISM-PLUS trial (platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms)
112. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients: Angiographic results from the CAPTURE trial
113. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention
114. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis
115. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction
116. Tirofiban and eptifibatide, but not abciximab, induce leukocyte-platelet aggregation
117. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
118. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters
119. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin alphaIIbbeta3 (GPIIb/IIIa) antagonists, c7E3 and DMP728
120. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood
121. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa
122. RGD peptides induce apoptosis by direct caspase-3 activation
123. Fas-induced caspase denitrosylation
124. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the prevention of ischemic complications trial
125. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'
126. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa: Inhibition by RGDS and a Glanzmann's thrombasthenia defect
127. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity
128. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients
129. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
130. Ligands 'activate' integrin alphaIIbbeta3 (platelet GPIIb-IIIa)
131. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors
132. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation
133. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction
134. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in myocardial infarction
135. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement
136. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists
137. Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses
138. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation of PTCA to improve long-term outcome with abciximab GPIIb/IIIa receptor blockade
139. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions
140. The benefit of abciximab in percutaneous coronary revascularization is not device-specific
141. Periprocedural myocardial infarction
142. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures
143. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions
144. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention
145. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
146. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
147. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
148. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of platelet IIb/IIIa inhibition in stenting investigators
149. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
150. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy
151. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
152. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
153. Clinical outcomes of therapeutic agents that block the platelet glycoprotein Ilb/IIIa integrin in ischemic heart disease
154. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
155. Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: Applicability to the practice of medicine in the United States
156. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
157. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM study investigators. Platelet receptor inhibition in ischemic syndrome management
158. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
159. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial
160. Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
161. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
162. Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion. The GUSTO investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries
163. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
164. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial
165. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study
166. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo- controlled, dose-ranging trial
167. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
168. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
169. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial
170. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
171. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomized trial in acute myocardial infarction
172. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
173. Platelet glycoprotein IIb/IIIa blockers